AstraZeneca PLC / LogicBio Therapeutics Inc.

Methylmalonic Acidemia (MMA) and Pediatric Rare Genetic Diseases

500 US cases/yr · $300M Estimated peak addressable rare metabolic gene therapy opportunity

Disease Overview

Methylmalonic acidemia (MMA) is an ultra-rare autosomal recessive inborn error of metabolism caused most commonly by mutations in the MUT gene encoding methylmalonyl-CoA mutase, leading to toxic accumulation of methylmalonic acid, recurrent metabolic crises, neurologic injury, chronic kidney disease, and high pediatric mortality. U.S. prevalence is estimated at roughly 1 in 50,000-100,000 live births, translating to a few hundred newly diagnosed pediatric patients each year and a prevalent population of 1,500-3,000. Standard-of-care is restricted to lifelong protein-restricted diet, hydroxocobalamin supplementation in B12-responsive subtypes, and liver-kidney transplant in advanced cases - there is no disease-modifying drug approved. The MMA opportunity is the lighthouse indication for a broader rare pediatric in-vivo gene editing strategy because the liver-restricted phenotype, well-defined biomarkers (plasma and urine methylmalonate), and severe untreated natural history offer a tractable proof-of-concept for AAV-based GeneRide and CRISPR-class platforms targeting other monogenic pediatric metabolic, hematologic, and CNS diseases that Alexion's rare-disease franchise sits over.

Competitive Landscape

The pediatric MMA and broader monogenic metabolic gene-therapy landscape has very few approved or late-stage assets. There is no FDA-approved disease-modifying therapy for MMA - care is supportive and transplant. Moderna/mRNA-3705 (mRNA encoding human MUT enzyme) was the most clinically advanced asset at deal time, in Phase 1/2 (Landmark trial), with first-in-human dosing 2022. CRISPR Therapeutics and Verve had general in-vivo lipid-nanoparticle platforms but were not pursuing MMA. The competitive set for the broader Alexion/AstraZeneca rare-disease in-vivo editing thesis includes Intellia Therapeutics' NTLA-2001 (transthyretin amyloidosis, Phase 1) using LNP-CRISPR, Verve Therapeutics' VERVE-101 (PCSK9 base editing, Phase 1b), Beam Therapeutics' BEAM-201/302/301 base editors, and Editas Medicine's CRISPR programs. LogicBio's GeneRide platform - homologous-recombination-based AAV gene insertion at the albumin locus - was differentiated as a non-nuclease, integration-based approach competitive with Homology Medicines' GTX-201 (HMI-103). Post-deal Alexion folds GeneRide into the AstraZeneca rare-disease pipeline alongside ALXN1840 (Wilson disease), KOSELUGO and the Ultragenyx-style ultra-rare playbook.